null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222235

Enrollment

885

Registered

2013-09-27

Start date

2013-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Tildrakizumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Invest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy efficacy safety safety safety safety	—

Secondary

Measure	Time frame
efficacy efficacy efficacy efficacy	—

Countries

Europe, Japan, North America, Oceania

Outcome results